Dr Norman Arons at South Florida Eye Clinic is pleased to announce that genetic testing is now being offered for patients with Age-related Macular Degeneration (AMD).
Combined with a routine clinical eye examination, results of the Macula Risk® PGx test, and Vita Risk™ test help determine which patients are at the highest risk of vision loss from AMD, and guide us in prescribing the safest, most effective eye vitamin formulations, and disease management programs.
The Age-Related Eye Disease Study (AREDS) has demonstrated that eye vitamins can protect a significant percentage of patients from developing advanced AMD. Recent data suggests, however, that ingredients within the commonly prescribed AREDS formulation, specifically antioxidants and zinc, may be helpful or harmful to some patients based on their genetics.
Looking for two critical AMD genes, CFH and ARMS2, it provides a report that lets us know whether you would benefit most from the complete AREDS formulation; a formulation containing antioxidants alone; or a formulation containing zinc alone. The tests allows us to identify and better manage high-risk patients through disease education, at-home vision monitoring, lifestyle modifications and an increased frequency of eye examinations where necessary.
Both the Macula Risk PGx and Vita Risk tests use a simple cheek swab that is covered by most insurers.